MissionIR today released its interview with CytRx President and Chief Executive Officer Steven Kriegsman, as well as the company’s Vice President of Business Development and Investor Relations David Haen. The full audio interview is available at: http://cytr.missionir.com/interview.html.
CytRx is a biopharmaceutical R&D company developing cancer drugs for several indications. The company’s primary focus is on its proprietary delivery technology for potent oncology therapies.
The company’s lead candidate, aldoxorubicin, is an improved version of the widely used chemotherapy agent, doxorubicin. A pivotal Phase 3 trial with a special protocol assessment is scheduled to begin in the first quarter of 2014 and top-line Phase 2b results are expected in December 2013. These are just a few developments in the company’s pipeline, which are further detailed in the interview.
“We have a technology that allows us to optimize chemotherapy agents as well as other anti-cancer agents,” Haen stated in the interview, describing aldoxorubicin and reinforcing Kriegsman’s statements. “We’re not seeing nearly the systemic toxicity one typically thinks of when you hear of chemotherapy… here we think we have a way to optimize it. Aldoxorubicin is really the proof of principal and the goal is to work with our collaborators in Freiburg, Germany, to develop additional molecules based on other chemotherapy payloads.
Kriegsman and Haen discuss their own backgrounds and experience in the industry, as well as detail the rest of the company’s management team.
Wrapping up the interview, Kriegsman highlights 2013 achievements and provides insight to recent company news and important upcoming developments.
To view the full transcript, visit http://www.marketwired.com/press-release/MissionIR-Releases-Exclusive-Audio-Interview-With-CytRx-Management-NASDAQ-CYTR-1849549.htm
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
